NPM1-mutated AML prognosis was refined using a new genetic model integrating co-mutations, improving risk classification and ...

Researchers sought to determine whether combining enasidenib with venetoclax would be effective in patients with IDH2-mutated ...

HOUSTON -- Complete response (CR) rates in relapsed/refractory NPM1-mutated acute myeloid leukemia (AML) doubled historical rates in a preliminary study of an investigational menin inhibitor. A pooled ...

SAN DIEGO — Allogeneic stem cell transplant is associated with a significant survival benefit in patients with NPM1-mutated acute myeloid leukemia (AML) who are in their first complete remission and ...

Ivosidenib plus azacitidine significantly prolongs median overall survival in patients with IDH1-mutated acute myeloid leukemia (AML), with a median overall survival of 29.3 months versus 7.9 months ...

SELLAS Life Sciences Group, Inc. has announced promising preclinical results for SLS009, a selective CDK9 inhibitor, in treating TP53 mutated Acute Myeloid Leukemia (AML) cells, which typically have ...

Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML – – $2.1 million ...

Revumenib demonstrates significant efficacy in R/R AML with NPM1m, KMT2Ar, and NUP98r, showing high response rates and tolerability. The AUGMENT-101 study reports a 26% CR/CRh rate in NPM1-mutated AML ...

Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN ...